Immunotherapy has emerged as an important treatment modality throughout oncology with a particularly important role in the treatment of lung cancer. Early signals showed responses could be achieved in nonsmall cell lung cancer and small cell lung cancer and these monoclonal antibodies have become standards of care for advanced stage disease. They have also shown promise in earlier-stage disease as complements to radiation or surgery, offering the potential for durable, meaningful survival gains.
Keywords: PD-1; PD-L1; checkpoint inhibitors; chemo-immunotherapy; neoadjuvant.
© 2020 Wiley Periodicals LLC.